[
    [
        {
            "time": "",
            "original_text": "一季度业绩预增翻倍 贝达药业被追问是否存在向经销商压货",
            "features": {
                "keywords": [
                    "一季度",
                    "业绩预增",
                    "贝达药业",
                    "经销商",
                    "压货"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一季度业绩预增翻倍 贝达药业被追问是否存在向经销商压货",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "一季度盈利涨一倍多、股东飙升，贝达药业遭监管质疑向经销商压货 其他违规处罚",
            "features": {
                "keywords": [
                    "一季度",
                    "盈利增长",
                    "贝达药业",
                    "监管质疑",
                    "经销商",
                    "压货",
                    "违规处罚"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一季度盈利涨一倍多、股东飙升，贝达药业遭监管质疑向经销商压货 其他违规处罚",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业被问询，要求补充说明埃克替尼销量增长的原因及合理性 问询",
            "features": {
                "keywords": [
                    "贝达药业",
                    "问询",
                    "埃克替尼",
                    "销量增长",
                    "原因",
                    "合理性"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业被问询，要求补充说明埃克替尼销量增长的原因及合理性 问询",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]